NeoGenomics Reports Strong Preliminary Q4 & FY25 Revenue, Announces CFO Transition

summarizeSummary

NeoGenomics announced preliminary unaudited revenue for Q4 and full-year 2025, showing double-digit growth, alongside a planned and smooth transition of its Chief Financial Officer.

check_boxKey Events

• Preliminary Revenue Growth Reported

  NeoGenomics expects preliminary unaudited Q4 2025 revenue of approximately $190 million, representing 11% year-over-year growth, and full-year 2025 revenue of $727 million, representing 10% year-over-year growth.

• Chief Financial Officer Retirement Announced

  Jeffrey S. Sherman, the current CFO, will transition to Executive Vice President, Finance on March 2, 2026, and then retire on April 14, 2026, continuing as a special advisor through April 2028.

• New CFO Appointed

  Abhishek Jain, formerly CFO of CareDx, has been appointed Executive Vice President, Finance, effective January 12, 2026, and is expected to assume the CFO role on March 2, 2026.

• New CFO Compensation Details

  Mr. Jain's compensation includes an annual base salary of $520,000, a target annual incentive bonus of 60% of salary, and an initial equity grant of $2,750,000 (50% RSUs, 50% premium-priced stock options vesting over three years).

auto_awesomeAnalysis

NeoGenomics' preliminary financial results indicate robust performance with double-digit year-over-year revenue growth for both the fourth quarter and full fiscal year 2025, suggesting strong business momentum. The planned retirement of the current CFO, Jeffrey Sherman, with a structured transition to an advisory role, ensures continuity. The appointment of Abhishek Jain, an experienced finance executive from CareDx and Agilent Technologies, as the incoming CFO is a positive development, reinforcing the company's financial leadership.